Detect molecular players in arthritis pathology in vivo with PerkinElmer’s IVISense™ Arthritis Fluorescent Imaging Panel.
Standard methods to assess arthritis in animal models typically involve external measurements of limbs such as paw volume, paw thickness, and redness. While these methods determine the overall progression of disease, they do not access the underlying biology associated with the visible effects of the disease. Since arthritis involves not only inflammation pathways but also changes in vasculature and bone morphology, using fluorescent agents that measure each of these changes individually allow for a more complete assessment of the overall clinical pathology.
PerkinElmer's IVISense Arthritis fluorescent panel contains a carefully selected, pre-validated bundle of probes designed for researchers to gain a better understanding of arthritis disease and its progression.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The biology of arthritis is complex, involving multiple cellular players, secreted factors, and processes that can lead to sever joint damage. Our fluorescent imaging probes targeting arthritis research allows in vivo imaging of the magnitude of inflammation, bone destruction, cartilage degradation, and vascular leak (edema) in a manner that non-invasively predicts the underlying histopathology of this disease.
The availability of probes at 680 nm and 750 nm wavelengths further offer the opportunity for multiplex imaging of appropriate probe combinations to maximize information gained from research animals.
IVISense Arthritis Fluorescent Imaging Panel includes the following six probes:
|Part Number||Fluorescent Probe||Biological Target|
|NEV10003||IVISense Pan Cathepsin 680 (ProSense 680)||Pan-cathepsin activatable probe:
Lysosomal marker of inflammatory cells
|NEV10011EX||IVISense Vascular 750 (AngeioSense 750EX)||Vascular probe:
Leaks into sites of edema
|NEV10020EX||IVISense Osteo 680 (OsteoSense 680EX)||Bone turnover targeted probe:
Detects areas of exposed hydroxyapatite
|NEV10126||IVISense MMP 680 (MMPSense 680)||Pan-MMP activatable probe:
Secreted marker of inflammatory cells, bone/cartilage degradation
|NEV11000||IVISense Cat K 680 FAST||Cathepsin K activatable probe:
Secreted marker of osteoclasts, bone degradation
|NEV11098||IVISense Cat B 750 FAST||Cathepsin B activatable probe:
Lysosomal marker of inflammatory cells
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||6.0 Vials|
|Shipping Condition||Blue Ice|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
Data sheet on PerkinElmer's Fluorescent Panels for In Vivo imaging
User guide for fluorescent imaging probes
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.